Dr. Christine Laronga, MD

Dr. Laronga practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Laronga's NPI, 1659398402, was assigned on July 17, 2006. Dr. Laronga graduated from Rutgers New Jersey Medical School in 1991. Dr. Laronga holds Florida license ME93499.

Dr. Laronga's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Laronga also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Laronga's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Laronga to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Laronga practices, 4 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Laronga's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Laronga is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Laronga's licenses on file in 4 states: Florida, Virginia, New Jersey and Texas.

Dmand AI lists mastectomy among the conditions Dr. Laronga treats.

CMS data shows 295 Medicare services from Dr. Laronga across 9 procedure codes in 2024, for 174 Medicare patients. Medicare paid $56,619 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 174 Medicare patients who saw Dr. Laronga in 2024. The largest group is 65 to 74, with 106 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Laronga's median patient age at 64, with 98% women.

In 2024, Dr. Laronga wrote 46 Medicare Part D claims for 41 patients. 100% of them were for generic drugs. CMS names the drug for 31 of them, across 1 drug with 11 or more claims each, at $77 in total drug cost. In 2023, CMS named 40 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Laronga for performance year 2024, reported as part of a group. Dr. Laronga accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Laronga as offering telehealth. CMS counts 50 procedures of mastectomy by Dr. Laronga, more than 94% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 159 papers to Dr. Laronga, published from 2004 to 2025. 2023 was the busiest year, with 10. The most frequent topics are Breast Neoplasms, Mastectomy and Axilla. Dr. Laronga has published most often in Ann Surg Oncol. Dr. Laronga's most frequent co-authors are Marie Catherine Lee, MD, John Vincent Kiluk, MD and Nazanin I. Khakpour, MD.

Dmand AI links Dr. Laronga to 1 clinical trial. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 10 general payments to Dr. Laronga from 6 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 64% of the total. Carl Zeiss Meditec, Inc. paid the most, $1,103.

Dr. Laronga graduated from Rutgers New Jersey Medical School in 1991.

Dr. Laronga is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.